Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $24.5 million.

  • Veracyte's Cost of Revenue rose 815.05% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.0 million, marking a year-over-year increase of 331.59%. This contributed to the annual value of $95.4 million for FY2024, which is 596.71% down from last year.
  • Latest data reveals that Veracyte reported Cost of Revenue of $24.5 million as of Q3 2025, which was up 815.05% from $25.3 million recorded in Q2 2025.
  • Over the past 5 years, Veracyte's Cost of Revenue peaked at $26.1 million during Q1 2023, and registered a low of $16.3 million during Q1 2021.
  • Over the past 5 years, Veracyte's median Cost of Revenue value was $24.2 million (recorded in 2024), while the average stood at $23.6 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 9780.92% in 2021, then crashed by 898.58% in 2024.
  • Veracyte's Cost of Revenue (Quarter) stood at $22.2 million in 2021, then increased by 8.62% to $24.1 million in 2022, then rose by 4.7% to $25.3 million in 2023, then decreased by 1.73% to $24.8 million in 2024, then dropped by 1.49% to $24.5 million in 2025.
  • Its Cost of Revenue was $24.5 million in Q3 2025, compared to $25.3 million in Q2 2025 and $24.5 million in Q1 2025.